Myricx Bio: Revolutionizing Cancer Treatment with Novel Payloads
July 12, 2024, 9:35 pm
Myricx Bio, a UK-based biotech company, has secured a whopping £90 million in Series A funding to develop a groundbreaking class of payloads for antibody-drug conjugates (ADCs). Led by Novo Holdings and Abingworth, this investment marks a significant milestone in the fight against cancer.
Myricx Bio, founded by Prof Ed Tate, Dr Roberto Solari, and Dr Andrew Bell, is on a mission to redefine cancer treatment with their innovative approach. By targeting N-myristoyltransferases (NMT), enzymes crucial for cancer cell survival, Myricx Bio aims to deliver complete and durable tumor regressions with minimal side effects.
The current landscape of ADCs is dominated by microtubule and topoisomerase inhibitors, but the rise of acquired resistance calls for a new, differentiated mechanism of action. Myricx Bio's NMTi ADCs have shown promising results in solid cancer models, offering hope for patients with refractory tumors.
With the new funding, Myricx Bio plans to advance its pipeline of NMTi ADCs through clinical proof of concept, focusing on clinically validated tumor-associated antigens. This strategic move aims to address unmet needs in oncology and pave the way for a new era of cancer treatment.
As a spinout from Imperial College London and the Francis Crick Institute, Myricx Bio is well-positioned to lead the charge in cancer research. The company will expand its operations in London, bolstering its R&D capabilities and bringing cutting-edge therapies to the forefront of medical innovation.
The addition of new investors, including British Patient Capital and Eli Lilly & Company, underscores the industry's confidence in Myricx Bio's potential. With a team of seasoned drug hunters and scientists at the helm, Myricx Bio is poised to make a significant impact in the fight against cancer.
In the words of Myricx Bio's CEO, Dr. Robin Carr, "We are entering a new phase of development, thanks to the support of our investors. With our expanded resources and expertise, we are ready to take Myricx Bio to the next level and bring hope to patients in need."
Myricx Bio's journey is just beginning, but the implications of their work are profound. By harnessing the power of NMTi ADCs, Myricx Bio is paving the way for a future where cancer treatment is not just effective, but truly transformative.
Myricx Bio, founded by Prof Ed Tate, Dr Roberto Solari, and Dr Andrew Bell, is on a mission to redefine cancer treatment with their innovative approach. By targeting N-myristoyltransferases (NMT), enzymes crucial for cancer cell survival, Myricx Bio aims to deliver complete and durable tumor regressions with minimal side effects.
The current landscape of ADCs is dominated by microtubule and topoisomerase inhibitors, but the rise of acquired resistance calls for a new, differentiated mechanism of action. Myricx Bio's NMTi ADCs have shown promising results in solid cancer models, offering hope for patients with refractory tumors.
With the new funding, Myricx Bio plans to advance its pipeline of NMTi ADCs through clinical proof of concept, focusing on clinically validated tumor-associated antigens. This strategic move aims to address unmet needs in oncology and pave the way for a new era of cancer treatment.
As a spinout from Imperial College London and the Francis Crick Institute, Myricx Bio is well-positioned to lead the charge in cancer research. The company will expand its operations in London, bolstering its R&D capabilities and bringing cutting-edge therapies to the forefront of medical innovation.
The addition of new investors, including British Patient Capital and Eli Lilly & Company, underscores the industry's confidence in Myricx Bio's potential. With a team of seasoned drug hunters and scientists at the helm, Myricx Bio is poised to make a significant impact in the fight against cancer.
In the words of Myricx Bio's CEO, Dr. Robin Carr, "We are entering a new phase of development, thanks to the support of our investors. With our expanded resources and expertise, we are ready to take Myricx Bio to the next level and bring hope to patients in need."
Myricx Bio's journey is just beginning, but the implications of their work are profound. By harnessing the power of NMTi ADCs, Myricx Bio is paving the way for a future where cancer treatment is not just effective, but truly transformative.